The component stock Novavax Pharmaceuticals closed up 47.64%, continuing its 98.66% increase on Friday (May 10); AC Immune rose 42.86%, MacroGenics rose 32.33% Humacyte, Prime Medicine, Beam, Twist Bioscience, Recursion Pharmaceuticals, Coherus BioScience
The component stock Novavax Pharmaceuticals closed up 47.64%, continuing its 98.66% increase on Friday (May 10); AC Immune rose 42.86%, MacroGenics rose 32.33% Humacyte, Prime Medicine, Beam, Twist Bioscience, Recursion Pharmaceuticals, Coherus BioSciences rose 16.60%-10.00% Novocure also rose 9.17%; Zent
Coherus BioSciences Is Maintained at Buy by Truist Securities
Coherus BioSciences Is Maintained at Buy by Truist Securities
Truist Securities: Maintaining the Coherus BioSciences (CHRS.US) rating, adjusted from buy to buy rating, and adjusted target price from $8.00 to $7.00.
Truist Securities: Maintaining the Coherus BioSciences (CHRS.US) rating, adjusted from buy to buy rating, and adjusted target price from $8.00 to $7.00.
Truist Securities Maintains Buy on Coherus BioSciences, Lowers Price Target to $7
Truist Securities analyst Robyn Karnauskas maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price target from $8 to $7.
Coherus BioSciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
There's been a notable change in appetite for Coherus BioSciences, Inc. (NASDAQ:CHRS) shares in the week since its quarterly report, with the stock down 16% to US$1.90. It looks to have been a d
Coherus BioSciences Is Maintained at Buy by HC Wainwright & Co.
Coherus BioSciences Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Raises Price Target to $12
HC Wainwright & Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and raises the price target from $11 to $12.
Coherus BioSciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 559.34% HC Wainwright & Co. $11 → $12 Maintains Buy 03/20/2024 504.4% HC Wainwright & Co. $13 →
Coherus BioSciences Shares Are Trading Lower After the Company Reported Better-than-expected Q1 Financial Results.
Coherus BioSciences Shares Are Trading Lower After the Company Reported Better-than-expected Q1 Financial Results.
Earnings Call Summary | Coherus BioSciences(CHRS.US) Q1 2024 Earnings Conference
The following is a summary of the Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript:Financial Performance:Coherus BioSciences reported a net product revenue of $76.7 million in Q1 2024
Buy Rating Affirmed for Coherus Biosciences Amid Strong Udenyca Sales and Strategic Financial Management
Coherus BioSciences Q1 2024 Adj EPS $(0.32) Misses $(0.24) Estimate, Sales $77.063M Miss $80.248M Estimate
Coherus BioSciences Q1 2024 Adj EPS $(0.32) Misses $(0.24) Estimate, Sales $77.063M Miss $80.248M Estimate
Coherus BioSciences | 10-Q: Quarterly report
Earnings Flash (CHRS) COHERUS BIOSCIENCES Posts Q1 Revenue $77.1M, Vs. Street Est of $83.8M
04:04 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (CHRS) COHERUS BIOSCIENCES Posts Q1 Revenue $77.1M, vs. Street Est of $83.8M
Coherus BioSciences 1Q Net $102.9M >CHRS
Coherus BioSciences 1Q Net $102.9M >CHRS
Coherus Biosciences Embarks on Strategic Financial Restructuring
Press Release: Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan -- New $38.7 million term loan with a May 2029 maturity -- -- $37.5 million royalty monetization financing based on futur
Coherus To Collaborate With Cancer Research Institute On Novel Combination Evaluating LOQTORZI With ENB Therapeutics' ENB-003 For Treatment Of Ovarian Cancer
Coherus To Collaborate With Cancer Research Institute On Novel Combination Evaluating LOQTORZI With ENB Therapeutics' ENB-003 For Treatment Of Ovarian Cancer
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its first quarter 2024 financial results will be released after market close on Thursday,
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8
No Data